Síndrome de Sjögren primario

Qin, 2015, Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, 74, 1983, 10.1136/annrheumdis-2014-205375 Maciel, 2017, Prevalence of primary Sjögren's syndrome in a US population-based cohort, Arthritis Care Res, 69, 1612, 10.1002/acr.23173 Ramos-Casals, 2014, Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry), Rheumatology, 53, 321, 10.1093/rheumatology/ket349 Maciel, 2017, Incidence and mortality of physician-diagnosed primary Sjögren syndrome: time trends over a 40-year period in a population-based US cohort, Mayo Clin Proc, 92, 734, 10.1016/j.mayocp.2017.01.020 Brito-Zerón, 2016, Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients, Ann Rheum Dis, 75, 348, 10.1136/annrheumdis-2014-206418 Shiboski, 2017, 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts, Arthritis Rheum, 69, 35, 10.1002/art.39859 Vitali, 2002, Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann Rheum Dis, 61, 554, 10.1136/ard.61.6.554 Seror, 2015, EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide, RMD Open, 1, e000022, 10.1136/rmdopen-2014-000022 Daniels, 1984, Labial salivary gland biopsy in Sjögren's syndrome, Arthritis Rheum, 27, 147, 10.1002/art.1780270205 Al-Hashimi, 2001, Reproducibility of biopsy grade in Sjögren's syndrome, J Oral Pathol Med, 30, 408, 10.1034/j.1600-0714.2001.300705.x Guellec, 2013, Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review, Autoimmun Rev, 12, 416, 10.1016/j.autrev.2012.08.001 Yarom, 2007, Immunoprofile of focal lymphocytic infiltration in minor salivary glands of healthy individuals, Oral Dis, 13, 274, 10.1111/j.1601-0825.2006.01278.x van Bijsterveld, 1974, Standardization of the lysozyme test for a commercially available medium. Its use for the diagnosis of the sicca syndrome, Arch Ophthalmol, 91, 432, 10.1001/archopht.1974.03900060446002 Whitcher, 2010, A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry, Am J Ophthalmol, 149, 405, 10.1016/j.ajo.2009.09.013 Theander, 2015, Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling, Arthritis Rheumatol, 67, 2427, 10.1002/art.39214 Bergum, 2016, Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity, Ann Rheum Dis, 75, 1494, 10.1136/annrheumdis-2015-207751 Wolska, 2016, Brief report: patients with primary Sjögren's syndrome who are positive for autoantibodies to tripartite motif-containing protein 38 show greater disease severity, Arthritis Rheum, 68, 724, 10.1002/art.39497 Haacke, 2017, Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development, Ann Rheum Dis, 76, 1781, 10.1136/annrheumdis-2017-211290 Jousse-Joulin, 2019, Video clip assessment of a salivary gland ultrasound scoring system in Sjögren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise, Ann Rheum Dis, 78, 967, 10.1136/annrheumdis-2019-215024 Chikui, 2000, Abnormal blood flow to the submandibular glands of patients with Sjögren's syndrome: Doppler waveform analysis, J Rheumatol, 27, 1222 Jousse-Joulin, 2007, Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis, Biol Targets Ther, 1, 311 Le Goff, 2017, Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren's syndrome, Arthritis Res Ther, 19, 269, 10.1186/s13075-017-1475-x Jousse-Joulin, 2017, Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability, RMD Open, 3, e000364, 10.1136/rmdopen-2016-000364 Binard, 2009, Is the blood B-cell subset profile diagnostic for Sjögren syndrome?, Ann Rheum Dis, 68, 1447, 10.1136/ard.2008.096172 Moutsopoulos, 1994, Sjögren's syndrome: autoimmune epithelitis, Clin Immunol Immunopathol, 72, 162, 10.1006/clin.1994.1123 Anaya, 2006, Genetic basis of Sjögren's syndrome. How strong is the evidence?, Clin Dev Immunol, 13, 209, 10.1080/17402520600876911 Bolstad, 2001, HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome, J Rheumatol, 28, 1554 Rischmueller, 1998, HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS), Clin Exp Immunol, 111, 365, 10.1046/j.1365-2249.1998.00504.x Font, 2002, The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome, Rheumatology, 41, 1025, 10.1093/rheumatology/41.9.1025 Miceli-Richard, 2007, Association of an IRF5 gene functional polymorphism with Sjögren's syndrome, Arthritis Rheum, 56, 3989, 10.1002/art.23142 Lu, 2010, Epigenetics in autoimmune disorders: highlights of the 10th Sjögren's syndrome symposium, Autoimmun Rev, 9, 627, 10.1016/j.autrev.2010.05.011 Alevizos, 2011, MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome, Arthritis Rheum, 63, 535, 10.1002/art.30131 Jonsson, 2007, Sjögren's syndrome – a plethora of clinical and immunological phenotypes with a complex genetic background, Ann N Y Acad Sci, 1108, 433, 10.1196/annals.1422.046 Dawson, 2006, Sjogrens syndrome--the non-apoptotic model of glandular hypofunction, Rheumatology, 45, 792, 10.1093/rheumatology/kel067 Kawakami, 2007, Toll-like receptor in salivary glands from patients with Sjögren's syndrome: functional analysis by human salivary gland cell line, J Rheumatol, 34, 1019 Spachidou, 2007, Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome, Clin Exp Immunol, 147, 497, 10.1111/j.1365-2249.2006.03311.x Ohyama, 2006, Severe focal sialadenitis and dacryoadenitis in NZM2328 mice induced by MCMV: a novel model for human Sjögren's syndrome, J Immunol, 177, 7391, 10.4049/jimmunol.177.10.7391 Deshmukh, 2009, Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function, J Oral Pathol Med, 38, 42, 10.1111/j.1600-0714.2008.00700.x Triantafyllopoulou, 2007, Persistent viral infection in primary Sjogren's syndrome: review and perspectives, Clin Rev Allergy Immunol, 32, 210, 10.1007/s12016-007-8004-7 Moutsopoulos, 1986, HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome, Ann Rheum Dis, 45, 677, 10.1136/ard.45.8.677 Manoussakis, 1999, Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome, Arthritis Rheum, 42, 229, 10.1002/1529-0131(199902)42:2<229::AID-ANR4>3.0.CO;2-X Dimitriou, 2002, CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation, Clin Exp Immunol, 127, 386, 10.1046/j.1365-2249.2002.01752.x Kapsogeorgou, 2001, Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjögren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells, Clin Exp Immunol, 124, 126, 10.1046/j.1365-2249.2001.01500.x Yannopoulos, 1992, Conjunctival epithelial cells from patients with Sjögren's syndrome inappropriately express major histocompatibility complex molecules, La(SSB) antigen, and heat-shock proteins, J Clin Immunol, 12, 259, 10.1007/BF00918149 Mitsias, 2006, Sjögren's syndrome: why autoimmune epithelitis?, Oral Dis, 12, 523, 10.1111/j.1601-0825.2006.01292.x Xanthou, 2001, “Lymphoid” chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation, Arthritis Rheum, 44, 408, 10.1002/1529-0131(200102)44:2<408::AID-ANR60>3.0.CO;2-0 Fox, 1994, Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome, J Immunol, 152, 5532, 10.4049/jimmunol.152.11.5532 Xanthou, 1999, CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome, Clin Exp Immunol, 118, 154, 10.1046/j.1365-2249.1999.01037.x Bodeutsch, 1993, Monotypic plasma cells in labial salivary glands of patients with Sjögren's syndrome: prognosticator for systemic lymphoproliferative disease, J Clin Pathol, 46, 123, 10.1136/jcp.46.2.123 Stott, 1998, Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome, J Clin Invest, 102, 938, 10.1172/JCI3234 Dörner, 2002, Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome, Arthritis Res, 4, 360, 10.1186/ar603 Ohyama, 1996, Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome, Arthritis Rheum, 39, 1376, 10.1002/art.1780390816 Amft, 2001, Chemokines and cell trafficking in Sjögren's syndrome, Scand J Immunol, 54, 62, 10.1046/j.1365-3083.2001.00970.x Christodoulou, 2008, Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors, Am J Pathol, 173, 1389, 10.2353/ajpath.2008.080246 Sakai, 2008, Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18, J Immunol, 181, 2898, 10.4049/jimmunol.181.4.2898 Bunim, 1965, The frequent occurrence of hypergammaglobulinemia and multiple tissue antibodies in Sjögren's syndrome, Ann N Y Acad Sci, 124, 852, 10.1111/j.1749-6632.1965.tb19007.x Scofield, 1999, Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins, Arthritis Rheum, 42, 199, 10.1002/1529-0131(199902)42:2<199::AID-ANR1>3.0.CO;2-1 Staikou, 2003, Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies, Clin Exp Immunol, 134, 143, 10.1046/j.1365-2249.2003.02246.x Blaschek, 1988, Anti-Golgi complex autoantibodies in patients with primary Sjögren's syndrome, Scand J Rheumatol, 17, 291, 10.3109/03009748809098799 Bartfeld, 1969, Distribution of rheumatoid factor activity in nonrheumatoid states, Ann N Y Acad Sci, 168, 30, 10.1111/j.1749-6632.1969.tb43092.x Skopouli, 1994, Liver involvement in primary Sjögren's syndrome, Br J Rheumatol, 33, 745, 10.1093/rheumatology/33.8.745 D’Arbonneau, 2003, Thyroid dysfunction in primary Sjögren's syndrome: a long-term follow-up study, Arthritis Rheum, 49, 804, 10.1002/art.11460 Bertram, 1964, A specific antibody against the epithelium of the salivary ducts in sera from patients with Sjögren's syndrome, Acta Allergol, 19, 458, 10.1111/j.1398-9995.1964.tb03284.x Haneji, 1997, Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome, Science, 276, 604, 10.1126/science.276.5312.604 Dawson, 2005, Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going?, Arthritis Rheum, 52, 2984, 10.1002/art.21347 Takemoto, 2005, Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjögren syndrome, Am J Med, 118, 181, 10.1016/j.amjmed.2004.07.049 Daridon, 2007, Polarization of B effector cells in Sjögren's syndrome, Autoimmun Rev, 6, 427, 10.1016/j.autrev.2007.01.010 Pers, 2008, B lymphocytes in Sjögren's syndrome, Rev Med Interne, 29, 1000, 10.1016/j.revmed.2008.01.018 Salomonsson, 2003, Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome, Arthritis Rheum, 48, 3187, 10.1002/art.11311 Weyand, 2003, Ectopic germinal center formation in rheumatoid synovitis, Ann N YAcad Sci, 987, 140, 10.1111/j.1749-6632.2003.tb06042.x Daridon, 2006, Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome, Arthritis Rheum, 54, 2280, 10.1002/art.21936 Larsson, 2005, Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjögren's syndrome and healthy subjects, Scand J Immunol, 61, 98, 10.1111/j.0300-9475.2005.01540.x Hansen, 2002, Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome, Arthritis Rheum, 46, 2160, 10.1002/art.10445 Youinou, 1988, CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome, J Autoimmun, 1, 185, 10.1016/0896-8411(88)90025-X Pers, 1999, The role of CD5-expressing B cells in health and disease (review), Int J Mol Med, 3, 239 Mackay, 2002, BAFF: a fundamental survival factor for B cells, Nat RevImmunol, 2, 465 Mariette, 2003, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome, Ann Rheum Dis, 62, 168, 10.1136/ard.62.2.168 Pers, 2005, BAFF overexpression is associated with autoantibody production in autoimmune diseases, Ann N YAcad Sci, 1050, 34, 10.1196/annals.1313.004 Daridon, 2007, Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome, Arthritis Rheum, 56, 1134, 10.1002/art.22458 Nardelli, 2001, Synthesis and release of B-lymphocyte stimulator from myeloid cells, Blood, 97, 198, 10.1182/blood.V97.1.198 Vora, 2003, Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function, J Immunol, 171, 547, 10.4049/jimmunol.171.2.547 Avery, 2003, BAFF selectively enhances the survival of plasmablasts generated from human memory B cells, J Clin Invest, 112, 286, 10.1172/JCI18025 Groom, 2002, Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome, J Clin Invest, 109, 59, 10.1172/JCI0214121 Xu, 2007, Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI, Nat Immunol, 8, 294, 10.1038/ni1434 Litinskiy, 2002, DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL, Nat Immunol, 3, 822, 10.1038/ni829 Hooks, 1979, Immune interferon in the circulation of patients with autoimmune disease, N Engl J Med, 301, 5, 10.1056/NEJM197907053010102 Gottenberg, 2006, Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome, Proc Natl Acad Sci U S A, 103, 2770, 10.1073/pnas.0510837103 Ittah, 2006, B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome, Arthritis Res Ther, 8, R51, 10.1186/ar1912 Groom, 2007, BAFF and MyD88 signals promote a lupus-like disease independent of T cells, J Exp Med, 204, 1959, 10.1084/jem.20062567 Zhong, 2018, The role of gut microbiota in the pathogenesis of rheumatic diseases, Clin Rheumatol, 37, 25, 10.1007/s10067-017-3821-4 de Paiva, 2016, Altered mucosal microbiome diversity and disease severity in Sjögren syndrome, Sci Rep, 6, 23561, 10.1038/srep23561 Seror, 2011, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome, Ann Rheum Dis, 70, 968, 10.1136/ard.2010.143743 Vitali, 2007, Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients, Arthritis Rheum, 56, 2223, 10.1002/art.22658 Seror, 2010, EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome, Ann Rheum Dis, 69, 1103, 10.1136/ard.2009.110619 Seror, 2010, Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index, Arthritis Care Res, 62, 551, 10.1002/acr.20173 Baimpa, 2009, Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects, Medicine, 88, 284, 10.1097/MD.0b013e3181b76ab5 Saraux, 2016, Treatment of primary Sjögren syndrome, Nat Rev Rheumatol, 12, 456, 10.1038/nrrheum.2016.100 Price, 2019, How to treat Sjögren's syndrome, Rheumatology, 10.1093/rheumatology/key363 Fox, 2019, Treatment of Sjögren's syndrome: current therapy and future directions, Rheumatology, 10.1093/rheumatology/kez142 Felten, 2019, The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials, Autoimmun Rev, 18, 576, 10.1016/j.autrev.2018.12.008 Sall, 2000, Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group, Ophthalmology, 107, 631, 10.1016/S0161-6420(99)00176-1 Shahin, 2014, The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients, Clin Rheumatol, 33, 925, 10.1007/s10067-014-2548-8 Gottenberg, 2014, Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial, JAMA, 312, 249, 10.1001/jama.2014.7682 Ramos-Casals, 2010, Treatment of primary Sjögren syndrome: a systematic review, JAMA, 304, 452, 10.1001/jama.2010.1014 Devauchelle-Pensec, 2014, Treatment of primary Sjögren syndrome with rituximab: a randomized trial, Ann Intern Med, 160, 233, 10.7326/M13-1085 Roon, 2019, Thu0238 clinical efficacy of leflunomide/hydroxychloroquine combination therapy in primary Sjogren's syndrome is predicted by serum proteome biomarkers - Results from Repurpss-I, Ann Rheum Dis, 78, 396 Tobón, 2010, Emerging biotherapies for Sjögren's syndrome, Expert Opin Emerg Drugs, 15, 269, 10.1517/14728211003702392 Mariette, 2004, Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS), Arthritis Rheum, 50, 1270, 10.1002/art.20146 Sankar, 2004, Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial, Arthritis Rheum, 50, 2240, 10.1002/art.20299 Meiners, 2014, Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study), Ann Rheum Dis, 73, 1393, 10.1136/annrheumdis-2013-204653 Saraux, 2010, The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome, Autoimmun Rev, 9, 609, 10.1016/j.autrev.2010.05.007 Pijpe, 2005, Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study, Arthritis Rheum, 52, 2740, 10.1002/art.21260 Seror, 2007, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome, Ann Rheum Dis, 66, 351, 10.1136/ard.2006.057919 Meijer, 2010, Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 960, 10.1002/art.27314 Dass, 2008, Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study, Ann Rheum Dis, 67, 1541, 10.1136/ard.2007.083865 Devauchelle-Pensec, 2007, Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20), Arthritis Rheum, 57, 310, 10.1002/art.22536 Fisher, 2018, Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy, Ann Rheum Dis, 77, 412, 10.1136/annrheumdis-2017-212268 Meiners, 2015, Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome, Clin Exp Rheumatol, 33, 443 Steinfeld, 2006, Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study, Arthritis Res Ther, 8, R129, 10.1186/ar2018 Furie, 2008, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus, Arthritis Res Ther, 10, R109, 10.1186/ar2506 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Mariette, 2015, Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis, 74, 526, 10.1136/annrheumdis-2013-203991 Dörner, 2019, Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity, Ann Rheum Dis, 78, 641, 10.1136/annrheumdis-2018-214720 Ramos-Casals, 2020, EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies, Ann Rheum Dis, 79, 3, 10.1136/annrheumdis-2019-216114